IE
MBX

Israel Englander’s MBX Biosciences MBX Stock Holding History

Israel Englander’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-25,000
Closed -$438K – 6570
2025
Q3 		$438K Sell
25,000
-26,300
-51% -$352K ﹤0.01% 5153
2025
Q2 		$585K Buy
+51,300
New +$523K ﹤0.01% 4797

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Israel Englander's MBX Position: Q2 2026 in Review

Israel Englander reduced its MBX Biosciences (MBX) stake by 60% in Q2 2026, selling an estimated $11.8M and leaving 226,151 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

Israel Englander first reported a position in MBX in Q3 2024 and has held it in 8 quarters since. The position peaked at $16.8M in Q1 2026. 171 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Israel Englander held 226,151 shares of MBX Biosciences worth $12.5M as of Q2 2026.
  • Israel Englander sold 338,264 MBX Biosciences shares in Q2 2026, an estimated $11.8M.
  • MBX Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2065 holding.
  • Israel Englander first reported a position in MBX Biosciences in Q3 2024 and has held it in 8 quarters since.
  • Israel Englander's MBX Biosciences position peaked at $16.8M in Q1 2026.
  • 171 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.